PureTech Reports LYT-200 Phase 1b Results, Plans Phase 2
PureTech reported a 45.5% overall response rate among 11 evaluable HR-MDS patients treated with LYT-200 plus HMA, with favorable safety. Gallop plans a 125-patient randomized Phase 2, subject to external capital.
PureTech reported Phase 1b results for LYT-200 in R/R HR-MDS/AML, including a 45.5% ORR in 11 evaluable HR-MDS patients on LYT-200+HMA, with favorable safety. Gallop plans a 125-patient randomized Phase 2, subject to external capital.Material DetailsContext by AI AnalystThis is early clinical valid…